Mainz Biomed NVNASDAQ:MYNZ
- LAST PRICE5.6114
- TODAY'S CHANGE (%)0.1214 (2.2113%)
- Bid / Lots5.4100/ 2
- Ask / Lots5.7000/ 2
- Open / Previous Close5.5000 / 5.4900
- Day Range
- 52 Week Range
- Volume18,787
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYNZ |
|---|---|---|
| 09:32 ET | 3060 | 5.69 |
| 09:38 ET | 300 | 5.6899 |
| 09:39 ET | 3800 | 5.56 |
| 09:43 ET | 835 | 5.6299 |
| 09:48 ET | 1000 | 5.63 |
| 09:50 ET | 900 | 5.515 |
| 10:01 ET | 361 | 5.6 |
| 10:03 ET | 100 | 5.5 |
| 10:06 ET | 1000 | 5.52 |
| 10:19 ET | 110 | 5.63 |
| 10:32 ET | 2650 | 5.69 |
| 10:33 ET | 2100 | 5.75 |
| 10:37 ET | 100 | 5.52 |
| 10:46 ET | 200 | 5.71 |
| 11:06 ET | 150 | 5.6114 |
Yesterday
Mainz Biomed Partnering With TESTDNA Katowice to Market ColoAlert Test in Poland, from 4:38AM ET on Wednesday May 31, 2023 by MT Newswires
4:38AM ET on Wednesday May 31, 2023 by MT NewswiresMainz Biomed Expands Commercial Footprint into Poland, from 3:01AM ET on Wednesday May 31, 2023 by GlobeNewswire
3:01AM ET on Wednesday May 31, 2023 by GlobeNewswire
May 24, 2023
May 18, 2023
--Cantor Fitzgerald Adjusts Price Target on Mainz Biomed to $12 From $15, Keeps Overweight Rating, from 11:02AM ET on Thursday May 18, 2023 by MT Newswires
11:02AM ET on Thursday May 18, 2023 by MT Newswires
May 16, 2023
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update, from 3:01AM ET on Tuesday May 16, 2023 by GlobeNewswire
3:01AM ET on Tuesday May 16, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mainz Biomed NV | 81.4M | 0.0x | --- |
Streamline Health Solutions Inc | 87.9M | -6.5x | --- |
Global Cord Blood Corp | 398.3M | 5.2x | +20.97% |
BioNexus Gene Lab Corp | 50.0M | -112.4x | --- |
Arboreta Healthcare Inc | 45.6M | 0.0x | --- |
Biodesix Inc | 109.8M | -1.0x | --- |
Company Information
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Contact Information
- Headquarters
- Sirius Gutenberg Park Robert-Koch-Strasse 50MAINZ, Germany 55129
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Guido Baechler
- Chief Financial Officer
- William Caragol
- Chief Operating Officer
- Philipp Freese
- Chief Scientific Officer, Director
- Moritz Eidens
- Independent Director
- Hans Hekland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $81.4M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 14.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $0.96 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
